Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03041363 · ClinicalTrials.gov registry record · Phase 1
Treatment Development of Triheptanoin (G1D)
A Phase 1 study of Epilepsy and Glucose Metabolism Disorders, sponsored by Juan Pascual.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03041363 is a Phase 1 study of Epilepsy and Glucose Metabolism Disorders that has completed, run by Juan Pascual. The registered enrollment target is 12 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03041363, a Phase 1 study of Epilepsy and Glucose Metabolism Disorders, has completed, sponsored by Juan Pascual.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the maximum tolerated dose (MTD), as a percentage of calories consumed, of triheptanoin (C7 oil; C7) in a pediatric and adult patient population genetically diagnosed with glucose transporter type 1 deficiency disorder (G1D).
Conditions Studied
Interventions
- DRUG Triheptanoin
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2017-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03041363
The ClinicalTrials.gov registry entry for NCT03041363 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The listed sponsor is Juan Pascual, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Triheptanoin is the first listed.
NCT03041363 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03041363 about?
NCT03041363 is a clinical study titled "Treatment Development of Triheptanoin (G1D)". To determine the maximum tolerated dose (MTD), as a percentage of calories consumed, of triheptanoin (C7 oil; C7) in a pediatric and adult patient population genetically diagnosed with glucose transporter type 1 deficiency disorder (G1D).
What is the current status of trial NCT03041363?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-03-29. Estimated completion is 2017-12-22.
What conditions does trial NCT03041363 study?
This clinical trial studies the following conditions: Epilepsy, Glucose Metabolism Disorders, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome.
What interventions are being tested in trial NCT03041363?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT03041363?
This trial is sponsored by Juan Pascual, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03041363 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.